RecruitingNCT06079554
Microbiota and Metabolomics of Intestinal Type of Gastric Cancer
Microbiota and Metabolomics of Intestinal Type of Gastric Cancer in the Context of Atrophic Gastritis
Sponsor
Jilin University
Enrollment
32 participants
Start Date
Mar 31, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Compare with the gastric cavity without cancerous transformation in atrophic gastritis, analyze the microbiota and metabolomics changes in intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- •Intestinal type of gastric cancer or atrophic gastritis
- Underwent Endoscopic submucosal dissection（ESD）
Exclusion Criteria2
- • have simultaneously other cancer
- have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06079554
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
NCT074811102 locations
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT0570222944 locations